Clinical trials: Streptococcal Pneumonia
Cystitis, Erysipelas
Hospital at Home for Elderly Acute Ill Patients
Many elderly patients with uncomplicated treatment courses are admitted unnecessarily, which is a burden for the patient and society. Studies show that Hospital at Home (HaH) treatment is an alternative to hospitalization.
- Conditions
- Cystitis, Erysipelas, Pneumonia
- Trial name
- NCT05360914
- Testing
- Hospital at Home (HaH) treatment, Standard hospital admission
- Where
- 3 sites in Denmark
- Volunteers
- 849 people
- Sponsor
- Defactum, Central Denmark Region
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia.
- Trial name
- NCT05183854
- Testing
- Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Utah
Covid19, Systemic Autoimmune Disease
Mental Health Consequences of COVID19 Infection in the French RMD Cohort
this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients…
- Conditions
- Covid19, Systemic Autoimmune Disease, Inflammatory Rheumatism, Auto Inflammatory Diseases
- Trial name
- MentCovid19RMD (NCT04510467)
- Where
- France
- Volunteers
- 296 people
- Sponsor
- University Hospital, Lille
Pneumococcal Disease
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults…
- Trial name
- NCT07284654
- Testing
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Where
- 30 sites in United States
- Volunteers
- 4,049 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Streptococcus Pneumonia, Streptococcus Pyogenes Infection
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions.
- Conditions
- Streptococcus Pneumonia, Streptococcus Pyogenes Infection, Neisseria Meningitides Meningitis
- Trial name
- RIPI (NCT04594785)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer
COVID-19, Viral Pneumonia
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19.
- Conditions
- COVID-19, Viral Pneumonia, Pneumonia Due to Streptococcus Pneumoniae, Bacterial Pneumonia
- Trial name
- PROVID-CAPNETZ (NCT04952337)
- Where
- 15 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Hannover Medical School
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Nasopharyngeal Carriage of S. Pneumoniae
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
The specific aim is to evaluate the impact of PCV13 as administered in the pediatric primary care clinic at Boston medical center on the serotype specific carriage of Streptococcus pneumoniae in children < 5.
- Trial name
- NCT01109108
- Where
- United States
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Pneumonia
Pneumococcal Adult-dose Ranging Immunization Study
The purpose of this study is to give seniors different doses of a new pneumococcal vaccine called PCV7 to evaluate the safety of the vaccine and compare the immune response to find out which amount gives the best immune response.
- Trial name
- NCT00169234
- Testing
- PCV7, Prevnar®, Pneumovax 23
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Kaiser Permanente
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
- Trial name
- NCT07425392
- Testing
- 31-valent pneumococcal conjugate vaccine, PCV20
- Where
- 30 sites in United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Carriage, Group A Streptococcus
Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees
The study is aimed at assessing pharyngeal and nasopharyngeal Streptococcus pneumonia carriage and pharyngeal Group A streptococcus carriage among field units new recruits.
- Conditions
- Carriage, Group A Streptococcus, Streptococcus Pneumonia
- Trial name
- NCT00808821
- Sponsor
- Medical Corps, Israel Defense Force
Pneumonia, Pneumococcal
Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months
The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT04108845
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Pneumonia, Pneumonia, Bacterial
Phase I to Test a New Pneumococcal Vaccine
To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.
- Trial name
- NCT03303976
- Testing
- Bioconjugate pneumococcal vaccine, Multivalent plain polysaccharide vaccine
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Streptococcus Pneumonia, Vaccine Preventable Disease
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
The current study provides data necessary to evaluate the safety and immunogenicity of Serum Institute of India's PNEUMOSIL® [Pneumococcal Polysaccharide Conjugate Vaccine Adsorbed (10-Valent)] in Healthy Vietnamese Infants and…
- Trial name
- PNEUMOSIL (NCT05140720)
- Testing
- PNEUMOSIL®
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Pneumococcal Vaccine
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
- Trial name
- NCT06337643
- Testing
- MVX01
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer